Nicholas A. Peppas, chair of The University of Texas at Austin’s Biomedical Engineering Department, has been elected a Corresponding Member of the Real Academia Nacional de Farmacia (Royal Academy of Pharmacy) of Spain.
George Georgiou, a professor at The University of Texas at Austin whose technology developments in the engineering, medical, biochemical and cellular fields could help treat tens of thousands of patients with diseases such as cancer and osteoporosis, has been elected as a member of the Institute of Medicine (IOM).
Katie Maass, a senior chemical engineering student in the Cockrell School of Engineering at The University of Texas at Austin, has been awarded a five-year $250,000 Hertz Foundation Fellowship to pursue graduate research that will fight cancer and improve drug delivery.
The nation's leading experts in biomedical engineering will meet in Austin Oct. 6-9 to network with top faculty and students from around the world, collaborate on new research and discuss the future of biomedical engineering, one of the fastest growing fields in the nation.
Miranda Denise Colletta and Cynthia Chen, undergraduates at The University of Texas at Austin, have been awarded Goldwater Scholarships, the premier undergraduate award of its type in mathematics, natural sciences and engineering.
Biomedical Engineers Get $11.6 Million from National Cancer Institute to Offer Non-traditional Cancer Research Approaches
The University of Texas at Austin Department of Biomedical Engineering is among a consortium of leading research entities from across the United States selected to receive up to $11.6 million from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.
Nicholas A. Peppas was elected today to the Institute of Medicine (IOM) of the National Academy of Sciences, becoming the first faculty member from The University of Texas at Austin to receive this honor—the highest recognition a scientist or engineer in the medical sciences can receive in the United States.
Insulin pills to replace the injections necessary for those suffering from diabetes appear closer to reality through new research by chemical and biomedical engineers at The University of Texas at Austin.